BiosimilarDrug
BAT1706 clinical trials
Also written BAT1706.
A product of Bevacizumab; its studies count on that page too.
- studies test it
- 3
- open now
- 0
- in phase 3
- 1
- first study started
- 2016
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
3 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses BAT1706 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 InjectionCompletedPhase 1Bio-Thera SolutionsNCT05865574Written as BAT1706 Injection
- A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung CancerCompletedPhase 3Bio-Thera SolutionsNCT03329911Written as BAT1706
- Study of Bevacizumab(BAT1706) and Comparators in Healthy SubjectsCompletedPhase 1Bio-Thera SolutionsNCT03030430Written as BAT1706 injection
Given in every arm · 2 — BAT1706 is usual care beside what is tested
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedPhase 3BeOne MedicinesNCT04164199Written as BAT1706
- A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCCompletedPhase 2BeiGeneNCT04948697Written as BAT1706